Drug intelligence / Profile preview

La-MC1RL-DOTA

Development stage: Preclinical
Lead developer: H. Lee Moffitt Cancer Center & Research Institute
Modality: Peptides
Administration: Intravenous

Overview

La-MC1RL-DOTA is a non-radioactive lanthanum-labeled version of the MC1R-specific ligand (MC1RL) conjugated to the DOTA chelator. It was developed as a control agent for the targeted alpha therapy 225Ac-MC1RL-DOTA. The ligand, MC1RL, has high affinity and selectivity for the melanocortin 1 receptor (MC1R), which is highly expressed in uveal and cutaneous melanomas but not in most normal tissues. In preclinical studies, La-MC1RL-DOTA was used as a non-radioactive control to evaluate the efficacy of the alpha-emitting counterpart in mouse models of melanoma.

Targets

MC1R (Melanocortin Type 1 Receptor)

Beyond the preview

Go deeper on La-MC1RL-DOTA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on La-MC1RL-DOTA.

Explore the full profile